Scarica l'app Stockscreener
1.07
4.46%
-0.05
Dopo l'orario di chiusura:
1.06
-0.01
-0.93%
Precedente Chiudi:
$1.12
Aprire:
$1.105
Volume 24 ore:
1.19M
Relative Volume:
0.23
Capitalizzazione di mercato:
$31.33M
Reddito:
$1.20M
Utile/perdita netta:
$-22.70M
Rapporto P/E:
-0.8228
EPS:
-1.3005
Flusso di cassa netto:
$-19.24M
1 W Prestazione:
+9.98%
1M Prestazione:
+96.33%
6M Prestazione:
+39.83%
1 anno Prestazione:
-31.41%
Intervallo 1D:
$1.04
$1.15
Intervallo di 1 settimana:
$0.876
$1.15
Portata 52W:
$0.475
$1.83
Longeveron Inc Stock (LGVN) Company Profile
Nome
Longeveron Inc
Settore
Industria
Telefono
305-302-7158
Indirizzo
1951 NW 7TH AVENUE, MIAMI
Compare LGVN vs VRTX, REGN, ARGX, ALNY, INSM
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
LGVN
Longeveron Inc
|
1.07 | 31.33M | 1.20M | -22.70M | -19.24M | -1.3005 |
VRTX
Vertex Pharmaceuticals Inc
|
438.71 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
761.85 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
746.42 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
318.85 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
162.43 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Longeveron Inc Stock (LGVN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-12-06 | Iniziato | ROTH MKM | Buy |
Longeveron Inc Borsa (LGVN) Ultime notizie
Investment Review: Is Longeveron Inc exposed to currency risksEarnings Trend Report & Step-by-Step Trade Execution Guides - baoquankhu1.vn
LGVN Technical Analysis & Stock Price Forecast - Intellectia AI
[Form 4] Longeveron Inc. Insider Trading Activity - Stock Titan
Longeveron (LGVN) CMO has shares withheld to cover RSU tax obligations - Stock Titan
Longeveron (LGVN) CFO has 13,145 shares withheld to cover RSU tax - Stock Titan
Longeveron (LGVN) CEO has shares withheld to cover RSU tax bill - Stock Titan
Patterns Watch: Can Longeveron Inc outperform in the next rallyEarnings Recap Summary & Free Safe Capital Growth Stock Tips - baoquankhu1.vn
LGVN Stock Chart | LONGEVERON INC-A (NASDAQ:LGVN) - ChartMill
LGVN: Laromestrocel shows strong clinical progress and regulatory momentum across multiple indications - TradingView
Movement Recap: How cyclical is Longeveron Incs revenue stream2026 PreEarnings & Entry and Exit Point Strategies - baoquankhu1.vn
Is Longeveron Inc stock good for income investorsTrade Entry Summary & Target Return Focused Picks - baoquankhu1.vn
Moving Averages: Will Longeveron Inc stock hit new highs in YEAR2026 Rallies & Step-by-Step Trade Execution Guides - baoquankhu1.vn
(LGVN.O) | Stock Price & Latest News - Reuters
LGVN Stock Price, Quote & Chart | LONGEVERON INC-A (NASDAQ:LGVN) - ChartMill
Profit Review: Can Longeveron Inc outperform in the next rally2026 Major Catalysts & Reliable Price Breakout Alerts - baoquankhu1.vn
Longeveron Receives Extended Nasdaq Compliance Grace Period - tipranks.com
Longeveron Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView
Longeveron (NASDAQ: LGVN) granted more time to cure Nasdaq $1 bid rule - Stock Titan
Longeveron braces for Q4 results following recent funding boost - MSN
Longeveron Cancels Special Meeting, Reschedules Reverse Split Vote - TipRanks
Longeveron (NASDAQ: LGVN) shifts reverse split proposal to annual - Stock Titan
Longeveron Inc. (NASDAQ:LGVN) Q4 2025 earnings call transcript - MSN
Longeveron launches offering of up to 11.8M shares via warrants and stock units - MSN
Longeveron secures $15M financing with potential for additional $15M tied to trial milestones - MSN
If You Invested $1,000 in Longeveron Inc (LGVN) - Stock Titan
Returns Recap: What are Eureka Acquisition Corps earnings expectationsMarket Trend Report & Safe Entry Point Identification - baoquankhu1.vn
Aug Action: What is Longeveron Incs revenue forecastTrade Volume Report & Weekly Breakout Stock Alerts - baoquankhu1.vn
Experience real-time quotes, in-depth charts, and analyst ratings - webull.com
Longeveron Inc. (NASDAQ:LGVN) Q4 2025 Earnings Call Transcript - Insider Monkey
Longeveron's third-quarter 2026 HLHS trial outcomes may confirm the viability of its overall business approach—while its Alzheimer's program continues to divert focus - Bitget
Longeveron’s Alzheimer’s Program Faces High Late-Stage Failure Risk and Potential Pipeline Pressure - TipRanks
Longeveron (LGVN) shares surge on $30 million private placement deal - MSN
Longeveron Earnings Call: Pivotal Trials, Tight Cash - TipRanks
Insider Buy: Will Longeveron Inc benefit from rising consumer demand2026 Trading Volume Trends & Growth Oriented Trading Recommendations - baoquankhu1.vn
Treasury Yields: Is Longeveron Inc stock a value trap2026 Rallies & Risk Controlled Daily Plans - baoquankhu1.vn
LGVN shares rise after investigational therapy shows improvement in age-related frailty in study - MSN
Longeveron Inc. 2026 10-K: Clinical-Stage Biotech Advancing Laromestrocel (Lomecel-B) for Regenerative Medicine and Intellectual Property Expansion - Minichart
Longeveron Funding & Clinical Strategy: ELPIS II Results Expected Q3 2026News and Statistics - IndexBox
A Key "Master" Protein That Declines by Half After Age 40. One Company Found a Way to Restore It. - Benzinga
Longeveron (LGVN) Q4 2025 Earnings Call Transcript - AOL.com
Longeveron Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Longeveron Announces 2025 Full Year Financial Results and Provides Business Update - BioSpace
Earnings Call Summary | Longeveron(LGVN.US) Q4 2025 Earnings Conference - 富途牛牛
LGVN: $15M financing extends runway as pivotal HLHS trial nears, despite 50% revenue drop and higher losses - TradingView
Earnings call transcript: Longeveron reports Q4 2025 loss, raises capital By Investing.com - Investing.com Canada
Earnings call transcript: Longeveron reports Q4 2025 loss, raises capital - Investing.com
LONGEVERON ($LGVN) Releases Q4 2025 Earnings, Stock Rises - Quiver Quantitative
LGVN: Revenue fell 50% and net loss rose 41% in 2025, with pivotal HLHS trial results due Q3 2026 - TradingView
LGVN: 2025 net loss widened to $22.7M on lower revenue and higher R&D, with cash needs persisting - TradingView
Longeveron 10-K: Revenues $1.199M, Net Loss $(22.7)M - TradingView
Longeveron (NASDAQ: LGVN) advances laromestrocel cell therapy across HLHS and Alzheimer’s - Stock Titan
Longeveron Inc Azioni (LGVN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Longeveron Inc Azioni (LGVN) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Soffer Rock | Director |
May 29 '25 |
Sale |
1.30 |
10,000 |
13,000 |
220,034 |
0.49%
1.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):